A Phase 1/2 interventional study of Isatuximab SAR650984 and Atezolizumab in Neoplasm, sponsored by Sanofi. Terminated at 26 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-10.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objectives:
Secondary Objectives:
The total study duration per participant was up to 28 months including up to 28 days screening period, up to 24 months treatment period, and a 3 month safety follow up period.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 107 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with hepatocellular carcinoma (HCC) received atezolizumab 1200 milligrams, every 3 weeks (Q3W), intravenous (IV) infusion along with isatuximab 10 milligrams per kilogram (mg/kg), IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable adverse events (AE), participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 106 weeks).
Drug: Isatuximab SAR650984 · Drug: Atezolizumab
Participants with squamous cell carcinoma of the head and neck (SCCHN) received atezolizumab 1200 milligrams,Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 108 weeks).
Drug: Isatuximab SAR650984 · Drug: Atezolizumab
Participants with epithelial ovarian cancer (EOC) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 61 weeks).
Drug: Isatuximab SAR650984 · Drug: Atezolizumab
Participants with glioblastoma multiforme (GBM) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks).
Drug: Isatuximab SAR650984 · Drug: Atezolizumab
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Tecentriq®
Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs: AEs occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 thrombocytopenia with clinically significant bleeding/ G4 thrombocytopenia. Non-hematological abnormalities: G \>=2 Aspartate transaminase (AST)/ Alanine transaminase (ALT) elevation simultaneous with G \>=2 total bilirubin elevation without initial findings of cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that study committee deemed to be dose-limiting, regardless of grade, was also considered DLT.
Time frame: Cycle 1 (21 days)
Recommended Phase 2 Dose (RP2D)
RP2D was the starting dose selected for Phase 2 part of the study. RP2D was the selected dose at which no more than 1 out of 6 participants (starting dose or dose level minus -1 \[DL-1\]) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: Adverse Event (AE) occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7/ more consecutive days, G3 to G4 N with fever, G3/G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE.
Time frame: Cycle 1 (21 days)
Maximum Tolerated Dose (MTD)
MTD was defined as the highest dose level at which no more than 1 out of 6 participants (starting dose or DL-1) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: AE occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7 or more consecutive days, G3 to G4 N with fever, G3 or G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities or AEs.
Time frame: Cycle 1 (21 days)
Percentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts
OR was defined as the percentage of participants with complete response (CR) and partial response (PR) as best overall response, assessed per RECIST 1.1 criteria. Best overall response was derived per RECIST 1.1 criteria using disease assessments performed from the first dose of treatment throughout the study excluding any assessments performed after the cut-off date or following the initiation of a further anticancer treatment. CR was defined as the disappearance of all target lesions, pathological lymph nodes (target/non-target)- reduction in short axis \<10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum, sum with an absolute increase of diameter of at least 5 mm and appearance of \>1 new lesion.
Time frame: From randomization until disease progression, or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Probability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort
PFS-6 was defined as the probability of participants alive without disease progression at 6 months as assessed by RANO criteria. Participants who didn't experience documented progression or death before analysis cut-off date or date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. Per RANO criteria, progressive disease was defined as \>=25% increase size of T1- gadolinium enhancing disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status. PFS-6 was evaluated by Kaplan-Meier method.
Time frame: From randomization until 6 months after the last participant's first treatment in the GBM Cohort D-1
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Hematological Abnormalities
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Abnormal Electrolyte Parameters
Electrolyte parameters assessed were hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Renal Function Abnormalities
Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Liver Abnormalities
Abnormal liver function parameters assessed were AST increased, ALT increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure:106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Number of Participants With Anti-drug Antibodies (ADA) Response Against Atezolizumab
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.
Time frame: At start of infusion (SOI), end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
Time frame: At end of infusion on Cycle 1 Day 1
Pharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab
AUC0-168h was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using non-compartmental analysis after first infusion of isatuximab.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Trough Plasma Concentrations (Ctrough) of Isatuximab
Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.
Time frame: Pre-infusion on Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15
Plasma Concentration of Atezolizumab
Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1 and Cycle 16 Day 1
Best Percent Change From Baseline in Tumor Burden
Best tumor burden change was defined as the best percent-change from baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
Time frame: From randomization until progression or death or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)
Percentage of Participants With Disease Control (DC) >=6 Months
DC: percentage of participants with complete response (CR), partial response (PR) \& stable disease (SD) rate. RANO criteria, CR: no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable/ reduced (red) T2/FLAIR signal, no new lesion (NL), no corticosteroid use (CU) \& stable/ red clinical status (CS); PR: \>=50% change in size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/ red CU \& stable/ improved CS (ICS). SD: \<50% reduction to \<25% increase (inc) size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/red CU \& stable/ICS. Progressive disease (PD): \>=25% inc size of T1-Gd+ disease/ inc T2/FLAIR signal/ presence of NL/ worsening CS. RECIST criteria: CR: Disappearance of target lesions. Reduction in short axis to \<10 mm of lymph nodes; PR: 30% decrease in sum of diameters of target lesions; PD: 20% inc in sum of diameters of target lesions; SD: Neither sufficient shrinkage from baseline study to qualify for PR nor sufficient inc to qualify for PD.
Time frame: From the date of first response to disease progression or death, or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Duration of Response (DOR)
Time from date of 1st response until date of first documented recurrent/progressive disease (PD) or death whichever occurred 1st. In absence of disease progression or death before analysis cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1, CR: disappearance of all target lesions; PR: at least 30% decrease in sum of diameters of target lesions, PD: at least 20% increase in sum of diameters of target lesions. Per RANO criteria; CR: no change in size of T1-Gd+ disease, stable/reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable/improved status; PR: \>=50% change in size of T1-Gd+, stable/reduced T2/FLAIR signal, no new lesion, stable/reduced corticosteroid use, and stable/improved status. PD:\>=25% increase size of T1-Gd+/increased T2/FLAIR signal/presence of new lesion/worsening status.
Time frame: From the date of first response until disease progression or death, or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)
Progression-free Survival (PFS)
PFS was defined as time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever was 1st. Participants who didn't experience progression or death before analysis cut-off date/date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1 criteria, PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study. Appearance of 1 or more new lesions was also considered progression. Per RANO criteria, PD: \>=25% increase in product of perpendicular diameters of any target lesion, or worsening neurologic status not explained by causes unrelated to tumor progression.
Time frame: From date of first study treatment administration until disease progression or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Percentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort
Response rate for participants with GBM was defined as percentage of participants with CR \& PR as best overall response (BOR), assessed by Investigators using RANO criteria. BOR was derived per RANO criteria using disease assessments performed from 1st dose of treatment through study excluding any assessments performed after cut-off date or following initiation of further anticancer treatment. Per RANO criteria; CR was defined as no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; PR was defined as \>=50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status. Progressive disease was defined as \>=25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.
Time frame: From randomization until progression, or death, or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks for Cohort D-1)
Study was conducted at 26 active sites in 8 countries. A total of 107 participants were enrolled between 06 August 2018 and 21 July 2020 and received isatuximab in combination with atezolizumab. Study was planned to be conducted in 2 parts: Phase 1 (safety run-in) and Phase 2 (efficacy with a 2-stage design).
| Milestone | Cohort A: Hepatocellular Carcinoma (HCC): Isatuximab + Atezolizumab | Cohort B: Squamous Cell Carcinoma of the Head and Neck (SCCHN): Isatuximab + Atezolizumab | Cohort C: Epithelial Ovarian Cancer (EOC): Isatuximab + Atezolizumab | Cohort D-1: Glioblastoma Multiforme (GBM): Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Started | 27 | 29 | 18 | 33 |
| Completed | 1 | 3 | 0 | 0 |
| Not completed | 26 | 26 | 18 | 33 |
| Withdrew: Adverse event | 2 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 23 | 23 | 18 | 31 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 1 |
DLTs: AEs occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 thrombocytopenia with clinically significant bleeding/ G4 thrombocytopenia. Non-hematological abnormalities: G \>=2 Aspartate transaminase (AST)/ Alanine transaminase (ALT) elevation simultaneous with G \>=2 total bilirubin elevation without initial findings of cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that study committee deemed to be dose-limiting, regardless of grade, was also considered DLT.
| Participants | Isatuximab + Atezolizumab |
|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 |
RP2D was the starting dose selected for Phase 2 part of the study. RP2D was the selected dose at which no more than 1 out of 6 participants (starting dose or dose level minus -1 \[DL-1\]) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: Adverse Event (AE) occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7/ more consecutive days, G3 to G4 N with fever, G3/G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE.
| milligrams per kilogram (mg/kg) | Isatuximab + Atezolizumab |
|---|---|
| Recommended Phase 2 Dose (RP2D) | 10 |
MTD was defined as the highest dose level at which no more than 1 out of 6 participants (starting dose or DL-1) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: AE occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7 or more consecutive days, G3 to G4 N with fever, G3 or G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities or AEs.
| mg/kg | Isatuximab + Atezolizumab |
|---|---|
| Maximum Tolerated Dose (MTD) | 10 |
OR was defined as the percentage of participants with complete response (CR) and partial response (PR) as best overall response, assessed per RECIST 1.1 criteria. Best overall response was derived per RECIST 1.1 criteria using disease assessments performed from the first dose of treatment throughout the study excluding any assessments performed after the cut-off date or following the initiation of a further anticancer treatment. CR was defined as the disappearance of all target lesions, pathological lymph nodes (target/non-target)- reduction in short axis \<10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum, sum with an absolute increase of diameter of at least 5 mm and appearance of \>1 new lesion.
| percentage of participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab |
|---|---|---|---|
| Percentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts | 7.4 (1.3 to 21.5) | 13.8 (4.9 to 28.8) | 5.6 (0.3 to 23.8) |
PFS-6 was defined as the probability of participants alive without disease progression at 6 months as assessed by RANO criteria. Participants who didn't experience documented progression or death before analysis cut-off date or date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. Per RANO criteria, progressive disease was defined as \>=25% increase size of T1- gadolinium enhancing disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status. PFS-6 was evaluated by Kaplan-Meier method.
| probability of participants | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|
| Probability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort | 0.033 (0.002 to 0.145) |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).
| Participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| TEAE | 26 | 29 | 18 | 33 |
| TESAE | 12 | 16 | 8 | 9 |
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Anemia: Grade 1 | 11 | 13 | 6 | 7 |
| Anemia: Grade 2 | 5 | 12 | 6 | 2 |
| Anemia: Grade 3 | 2 | 3 | 0 | 0 |
| Anemia: Grade 4 | 0 | 0 | 0 | 0 |
| White blood cell decreased: Grade 1 | 9 | 5 | 4 | 12 |
| White blood cell decreased: Grade 2 | 2 | 1 | 2 | 3 |
| White blood cell decreased: Grade 3 | 0 | 0 | 1 | 0 |
| White blood cell decreased: Grade 4 | 0 | 0 | 0 | 0 |
| Platelet count decreased: Grade 1 | 11 | 5 | 5 | 10 |
| Platelet count decreased: Grade 2 | 1 | 0 | 0 | 0 |
| Platelet count decreased: Grade 3 | 1 | 1 | 0 | 0 |
| Platelet count decreased: Grade 4 | 1 | 0 | 0 | 0 |
| Lymphocyte count decreased: Grade 1 | 4 | 2 | 2 | 10 |
| Lymphocyte count decreased: Grade 2 | 8 | 14 | 7 | 12 |
| Lymphocyte count decreased: Grade 3 | 3 | 7 | 4 | 3 |
| Lymphocyte count decreased: Grade 4 | 0 | 4 | 0 | 1 |
| Neutrophil count decreased: Grade 1 | 3 | 1 | 0 | 1 |
| Neutrophil count decreased: Grade 2 | 0 | 0 | 3 | 2 |
| Neutrophil count decreased: Grade 3 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased: Grade 4 | 0 | 0 | 0 | 0 |
Electrolyte parameters assessed were hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Hyponatremia: Grade 1 | 9 | 12 | 8 | 4 |
| Hyponatremia: Grade 2 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 3 | 1 | 4 | 0 | 1 |
| Hyponatremia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 1 | 2 | 5 | 4 | 4 |
| Hypokalemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 3 | 0 | 2 | 0 | 0 |
| Hypokalemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 1 | 5 | 6 | 2 | 2 |
| Hyperkalemia: Grade 2 | 1 | 0 | 1 | 1 |
| Hyperkalemia: Grade 3 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 1 | 9 | 7 | 2 | 9 |
| Hypocalcemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 3 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 1 | 1 | 5 | 0 | 0 |
| Hypercalcemia: Grade 2 | 0 | 2 | 0 | 0 |
| Hypercalcemia: Grade 3 | 1 | 2 | 0 | 0 |
| Hypercalcemia: Grade 4 | 0 | 1 | 0 | 0 |
| Hypoalbuminemia: Grade 1 | 9 | 7 | 7 | 2 |
| Hypoalbuminemia: Grade 2 | 1 | 3 | 1 | 1 |
| Hypoalbuminemia: Grade 3 | 0 | 2 | 0 | 0 |
| Hypoalbuminemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 1 | 1 | 3 | 0 | 2 |
| Hypoglycemia: Grade 2 | 1 | 0 | 0 | 0 |
| Hypoglycemia: Grade 3 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hyperglycemia: Grade 1 | 10 | 7 | 2 | 8 |
| Hyperglycemia: Grade 2 | 5 | 6 | 2 | 0 |
| Hyperglycemia: Grade 3 | 1 | 0 | 0 | 2 |
| Hyperglycemia: Grade 4 | 0 | 1 | 0 | 0 |
| Hypernatremia: Grade 1 | 0 | 4 | 0 | 5 |
| Hypernatremia: Grade 2 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 3 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 4 | 0 | 0 | 0 | 0 |
Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| CrCl: >=60 - <90 mL/min/1.73m^2 | 8 | 13 | 10 | 16 |
| CrCl: >=30 - <60mL/min/1.73m^2 | 5 | 4 | 5 | 1 |
| CrCl: >=15 - <30 mL/min/1.73m^2 | 3 | 0 | 0 | 0 |
| CrCl: <15 mL/min/1.73m^2 | 0 | 1 | 0 | 0 |
| Creatinine increased: Grade 1 | 22 | 19 | 13 | 24 |
| Creatinine increased: Grade 2 | 2 | 2 | 2 | 0 |
| Creatinine increased: Grade 3 | 1 | 1 | 0 | 0 |
| Creatinine increased: Grade 4 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 1 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 3 | 5 | 7 | 5 | 3 |
| Hyperuricemia: Grade 4 | 1 | 1 | 1 | 0 |
Abnormal liver function parameters assessed were AST increased, ALT increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| AST increased: Grade 1 | 14 | 5 | 6 | 3 |
| AST increased: Grade 2 | 5 | 0 | 0 | 1 |
| AST increased: Grade 3 | 3 | 0 | 0 | 0 |
| AST increased: Grade 4 | 1 | 0 | 0 | 0 |
| ALT increased: Grade 1 | 11 | 8 | 6 | 11 |
| ALT increased: Grade 2 | 4 | 0 | 1 | 0 |
| ALT increased: Grade 3 | 2 | 0 | 0 | 1 |
| ALT increased: Grade 4 | 1 | 0 | 0 | 0 |
| ALP increased: Grade 1 | 12 | 13 | 7 | 0 |
| ALP increased: Grade 2 | 8 | 2 | 3 | 0 |
| ALP increased: Grade 3 | 2 | 0 | 1 | 0 |
| ALP increased: Grade 4 | 0 | 0 | 0 | 0 |
| BB increased: Grade 1 | 6 | 1 | 0 | 0 |
| BB increased: Grade 2 | 2 | 0 | 0 | 2 |
| BB increased: Grade 3 | 3 | 0 | 0 | 0 |
| BB increased: Grade 4 | 1 | 0 | 0 | 0 |
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
| count of participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Treatment-induced ADA | 2 | 0 | 1 | 1 |
| Treatment boosted ADA | 0 | 0 | 0 | 0 |
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
| count of participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Treatment-induced ADA | 2 | 2 | 1 | 0 |
| Treatment boosted ADA | 0 | 0 | 0 | 0 |
Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.
| micrograms per milliliter (mcg/mL) | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab | 219 ± 50.5 | 218 ± 48.7 | 262 ± 69.7 | 266 ± 66.7 |
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
| mcg/mL | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab | 216 ± 50.8 | 207 ± 54.9 | 251 ± 77.3 | 263 ± 68.8 |
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
| hours | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab | 4.00 (2.42 to 7.92) | 3.37 (2.08 to 8.95) | 6.83 (3.00 to 8.83) | 4.13 (2.65 to 8.38) |
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.
| mcg/mL | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab | 75.9 ± 35.3 | 67.8 ± 20.4 | 86.0 ± 22.2 | 103 ± 28.4 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
| hours | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab | 166 (75.4 to 191) | 167 (162 to 192) | 167 (152 to 212) | 166 (136 to 192) |
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
| micrograms*hour/milliliter (mcg*h/mL) | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab | 20000 ± 4570 | 19700 ± 4500 | 24400 ± 7120 | 26300 ± 6510 |
AUC0-168h was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using non-compartmental analysis after first infusion of isatuximab.
| mcg*h/mL | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab | 20200 ± 4510 | 19800 ± 4590 | 24300 ± 6500 | 26400 ± 6270 |
Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.
| mcg/mL | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Cycle 1 Day 1 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 8 | 67.4 ± 20.0 | 71.0 ± 25.9 | 88.6 ± 21.8 | 99.9 ± 26.9 |
| Cycle 1 Day 15 | 153 ± 46.8 | 121 ± 25.6 | 176 ± 33.6 | 231 ± 102 |
No measurements were reported for this outcome.
Best tumor burden change was defined as the best percent-change from baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
| percent change | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Best Percent Change From Baseline in Tumor Burden | 6.2 ± 31.5 | -3.4 ± 41.6 | 16.2 ± 51.1 | 196.6 ± 347.5 |
DC: percentage of participants with complete response (CR), partial response (PR) \& stable disease (SD) rate. RANO criteria, CR: no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable/ reduced (red) T2/FLAIR signal, no new lesion (NL), no corticosteroid use (CU) \& stable/ red clinical status (CS); PR: \>=50% change in size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/ red CU \& stable/ improved CS (ICS). SD: \<50% reduction to \<25% increase (inc) size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/red CU \& stable/ICS. Progressive disease (PD): \>=25% inc size of T1-Gd+ disease/ inc T2/FLAIR signal/ presence of NL/ worsening CS. RECIST criteria: CR: Disappearance of target lesions. Reduction in short axis to \<10 mm of lymph nodes; PR: 30% decrease in sum of diameters of target lesions; PD: 20% inc in sum of diameters of target lesions; SD: Neither sufficient shrinkage from baseline study to qualify for PR nor sufficient inc to qualify for PD.
| percentage of participants | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Percentage of Participants With Disease Control (DC) >=6 Months | 37.0 (21.7 to 54.7) | 41.4 (25.9 to 58.3) | 33.3 (15.6 to 55.4) | 3.0 (0.2 to 13.6) |
Time from date of 1st response until date of first documented recurrent/progressive disease (PD) or death whichever occurred 1st. In absence of disease progression or death before analysis cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1, CR: disappearance of all target lesions; PR: at least 30% decrease in sum of diameters of target lesions, PD: at least 20% increase in sum of diameters of target lesions. Per RANO criteria; CR: no change in size of T1-Gd+ disease, stable/reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable/improved status; PR: \>=50% change in size of T1-Gd+, stable/reduced T2/FLAIR signal, no new lesion, stable/reduced corticosteroid use, and stable/improved status. PD:\>=25% increase size of T1-Gd+/increased T2/FLAIR signal/presence of new lesion/worsening status.
| months | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Duration of Response (DOR) | 7.5 ± 3.0 | 20.6 ± 7.3 | 10.4 | — |
PFS was defined as time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever was 1st. Participants who didn't experience progression or death before analysis cut-off date/date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1 criteria, PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study. Appearance of 1 or more new lesions was also considered progression. Per RANO criteria, PD: \>=25% increase in product of perpendicular diameters of any target lesion, or worsening neurologic status not explained by causes unrelated to tumor progression.
| months | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 2.04 (1.840 to 4.008) | 2.10 (1.873 to 3.253) | 2.04 (1.906 to 3.943) | 1.28 (1.216 to 1.380) |
Response rate for participants with GBM was defined as percentage of participants with CR \& PR as best overall response (BOR), assessed by Investigators using RANO criteria. BOR was derived per RANO criteria using disease assessments performed from 1st dose of treatment through study excluding any assessments performed after cut-off date or following initiation of further anticancer treatment. Per RANO criteria; CR was defined as no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; PR was defined as \>=50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status. Progressive disease was defined as \>=25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.
| percentage of participants | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|
| Percentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort | 0 (0.0 to 8.7) |
Collected over From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: HCC: Isatuximab + Atezolizumab | 4/27 (14.8%) | 12/27 (44.4%) | 25/27 (92.6%) |
| Cohort B: SCCHN: Isatuximab + Atezolizumab | 8/29 (27.6%) | 16/29 (55.2%) | 24/29 (82.8%) |
| Cohort C: EOC: Isatuximab + Atezolizumab | 3/18 (16.7%) | 8/18 (44.4%) | 18/18 (100%) |
| Cohort D-1: GBM: Isatuximab + Atezolizumab | 1/33 (3%) | 9/33 (27.3%) | 32/33 (97%) |
| Event | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Disease ProgressionGeneral disorders | 3/27 | 4/29 | 3/18 | 1/33 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/27 | 0/29 | 2/18 | 1/33 |
| Renal FailureRenal and urinary disorders | 2/27 | 0/29 | 0/18 | 0/33 |
| Tumour HaemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 2/29 | 0/18 | 0/33 |
| HemiparesisNervous system disorders | 0/27 | 0/29 | 0/18 | 2/33 |
| Malignant AscitesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 0/29 | 1/18 | 0/33 |
| Tumour Associated FeverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 0/29 | 1/18 | 0/33 |
| AnaemiaBlood and lymphatic system disorders | 1/27 | 0/29 | 1/18 | 0/33 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/27 | 0/29 | 1/18 | 0/33 |
| DehydrationMetabolism and nutrition disorders | 0/27 | 0/29 | 1/18 | 0/33 |
| Event | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 16/27 | 9/29 | 14/18 | 17/33 |
| FatigueGeneral disorders | 5/27 | 6/29 | 7/18 | 7/33 |
| HeadacheNervous system disorders | 3/27 | 4/29 | 1/18 | 12/33 |
| AstheniaGeneral disorders | 3/27 | 6/29 | 6/18 | 8/33 |
| DiarrhoeaGastrointestinal disorders | 2/27 | 3/29 | 5/18 | 4/33 |
| NauseaGastrointestinal disorders | 6/27 | 4/29 | 5/18 | 3/33 |
| PyrexiaGeneral disorders | 3/27 | 7/29 | 3/18 | 1/33 |
| Decreased AppetiteMetabolism and nutrition disorders | 6/27 | 2/29 | 3/18 | 1/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/27 | 0/29 | 4/18 | 1/33 |
| Abdominal PainGastrointestinal disorders | 6/27 | 0/29 | 4/18 | 2/33 |
Analysis was performed on all-treated population that included all the participants who signed the study informed consent and received at least 1 dose of the study treatments, either isatuximab or atezolizumab.
| Age, Continuous(years) | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab | Total |
|---|---|---|---|---|---|
| Mean | 62.8 ± 11.8 | 61.1 ± 9.1 | 56.3 ± 10.6 | 53.3 ± 13.3 | 58.3 ± 12.0 |
| Sex: Female, Male(Participants) | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab | Total |
|---|---|---|---|---|---|
| Female | 7 | 3 | 18 | 10 | 38 |
| Male | 20 | 26 | 0 | 23 | 69 |
| Race (NIH/OMB)(Participants) | Cohort A: HCC: Isatuximab + Atezolizumab | Cohort B: SCCHN: Isatuximab + Atezolizumab | Cohort C: EOC: Isatuximab + Atezolizumab | Cohort D-1: GBM: Isatuximab + Atezolizumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 11 | 9 | 4 | 0 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 15 | 20 | 13 | 29 | 77 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2018 to primary completion in May 2022, 45 months.
Results were first posted in Jun 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab